Bod Australia Ltd (ASX: BDA, “Bod”) has advised that it is continuing to experience significant uptake of its MediCabilis™ product amongst Australian patients.
What are the key highlights?
- During April 2020, Bod filled 516 prescriptions, marking a 35% increase on March 2020 (March prescriptions: 382) and the Company’s third largest volume month on record.
- The large volumes generated in April leave Bod well positioned to exceed Q3 MediCabilis™ prescriptions, which totalled 1,099.
- Bod has now filled a total of 3,459 prescriptions in FY2020, which has added significantly to the Company’s growing revenue profile.
- Repeat prescriptions for April accounted for 60% of the month’s total volume. The amount of repeat prescriptions achieved each month is increasing and the Company is confident this will continue as volumes grow.
For further details, please read the announcement linked below.